Market Overview

JP Morgan Comments on Potential Combination Of Valeant And Zoetis, Remains Overweight VRX and Neutral on ZTS

Related VRX
Exclusive: Clinical-Stage Specialty Pharma EyeGate CEO On Relationship With Valeant
Watch These 7 Huge Put Purchases In Thursday Trade
Saba Capital Management, L.P. Buys Allergan PLC, Alpine Total Dynamic Dividend Fund, , Sells ... (GuruFocus)
Related ZTS
Watch These 8 Huge Call Purchases In Monday Trade
Wall Street's M&A Chatter From January 18
Phibro Animal Health: Good Company, Good Performance, Questionable Price (Seeking Alpha)

The bank sees Zoetis as an 'attractive, durable, cash-pay business to Valeant's portfolio' and that a deal would be minimal accretive to EPS in the next 12 months. However, the deal would bring benefits in the longer run by aiding multiple expansion. Synergies remain elusive to those trying to identify them

Latest Ratings for VRX

Dec 2016Morgan StanleyDowngradesOverweightEqual-Weight
Nov 2016MizuhoDowngradesNeutralUnderperform
Nov 2016Morgan StanleyMaintainsOverweight

View More Analyst Ratings for VRX
View the Latest Analyst Ratings

Posted-In: Analyst Color Reiteration Analyst Ratings


Related Articles (VRX + ZTS)

View Comments and Join the Discussion!